Using Varenicline to Quit Vaping: Off-Label Evidence

Last reviewed: November 15, 2026Next review due: November 2027

Key takeaways

Health Canada says no quit aid is approved in Canada for quitting vaping. Varenicline is approved for smoking cessation in adults, so using it for vaping is off-label. A 2025 JAMA trial in 261 young people found 51% quit with it vs 14% on placebo, but adult evidence is small and uncertain.

Many people who want to stop vaping ask whether the pill used to quit cigarettes will work for them too. The honest answer from the sources we read is that it might, and that the evidence is newer and thinner than the evidence for smoking. This page summarizes what Health Canada says and what published trials found, as read on 15 November 2026. It is not medical advice, and only a prescriber can decide whether varenicline suits you.

Is varenicline approved for vaping in Canada?

No. Health Canada’s page on quitting vaping says quit aids have not been approved in Canada with the express purpose of helping someone quit vaping. It points readers to nicotine replacement therapy, prescription medications and cytisine, and tells them to ask a healthcare provider about a quit aid that is right for them.

The varenicline product monograph on Health Canada’s drug database says the drug is indicated for smoking-cessation treatment in adults, in conjunction with counselling. The copy we read was revised in March 2018, so a newer version may exist. Prescribing it for vaping would be off-label use.

What did the 2025 JAMA trial find?

The largest trial so far randomized 261 people aged 16 to 25 who vaped nicotine daily or near daily and did not regularly smoke tobacco. They received 12 weeks of varenicline, placebo or enhanced usual care. The first two groups also had weekly counselling and text support.

Continuous abstinence in weeks 9 to 12 was 51% on varenicline and 14% on placebo, an adjusted odds ratio of 6.5. In weeks 9 to 24 it was 28% against 7%. Against enhanced usual care, the rates were 51% vs 6% and 28% vs 4%. The authors concluded that varenicline with counselling increased vaping abstinence in this group. Two varenicline participants (2%) stopped the medication because of adverse events, and no drug-related serious adverse events occurred. The trial was run in one US state, and its participants did not regularly smoke cigarettes.

What about adults?

A small preliminary trial of 40 adults who vaped daily gave 8 weeks of varenicline or placebo. At week 8, 45% of the varenicline group and 30% of the placebo group had quit vaping, a difference too small to be conclusive in a trial that size. Common side effects were nausea, insomnia and vivid dreams or nightmares, and there were no serious adverse events.

What do the reviews say?

Two 2025 meta-analyses each pooled three randomized trials. The one from McGill-affiliated researchers covered 178 people on varenicline and 177 on placebo. Its pooled estimate for abstinence at maximum follow-up was a relative risk of 2.20, but the confidence interval ran from 0.58 to 8.36, so it could not rule out no benefit. It found about double the 7-day abstinence at the end of treatment, and concluded that larger trials are needed to confirm long-term efficacy and safety.

The other, covering 355 participants, reported a relative risk of 2.30 for 7-day abstinence at the end of treatment. It found nausea and vivid dreams were more frequent with varenicline. Both reviews were small, and they used slightly different outcomes, so treat the numbers as signals, not settled facts.

What should you ask a health professional?

Ask whether varenicline, nicotine replacement or another approach fits your age, health and history. Ask about nausea and sleep problems, which were the common side effects in the trials, and compare options in varenicline vs bupropion vs nicotine replacement. If you also smoke, the tools covered in medications to quit smoking in Canada apply directly. For non-prescription options see nicotine replacement for vaping, and for the general plan, how to quit vaping. Parents can start with the teen vaping quit guide.

What we could not confirm

  • A Canadian trial or guideline on varenicline for vaping. All the trials we read were done outside Canada.
  • Whether a newer version of the varenicline monograph changes the wording on age or indication.
  • Long-term results beyond the 24 weeks reported in the JAMA trial.
  • Provincial coverage for off-label use, which we did not check.

Health information is general and educational. It does not replace advice from a doctor, pharmacist or nurse. Read the full disclaimer.

Frequently asked questions

Is varenicline approved for quitting vaping in Canada?

No. Health Canada says quit aids have not been approved in Canada with the express purpose of helping someone quit vaping. The varenicline monograph we read lists smoking cessation in adults, with counselling, as the indication, so use for vaping is off-label.

Does varenicline work for vaping?

Trials suggest it may. A 2025 JAMA trial in people aged 16 to 25 found 51% quit with varenicline and counselling vs 14% on placebo in weeks 9 to 12. A small adult trial found 45% vs 30%, which was not conclusive. Meta-analyses call for larger trials.

What are the side effects of varenicline when used to quit vaping?

The adult trial reported nausea, insomnia and vivid dreams or nightmares as the most frequent. A 2025 meta-analysis found nausea and vivid dreams were more frequent with varenicline than placebo. The JAMA trial reported no drug-related serious adverse events.

Can teenagers take varenicline to quit vaping?

Health Canada's monograph says safety and efficacy in people under 18 have not been established and does not recommend it. The JAMA trial included 16 and 17 year olds, but it was run in one US state, so talk to a health professional.

Sources

  1. Quit vaping — Health Canada. Accessed November 15, 2026.
  2. Varenicline product monograph, revised March 1, 2018 — Health Canada (Drug Product Database). Accessed November 15, 2026.
  3. Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial (JAMA 2025) — PubMed (JAMA). Accessed November 15, 2026.
  4. Varenicline for E-Cigarette Cessation in Adults: A Preliminary Placebo-Controlled Randomized Trial — American Journal of Preventive Medicine (PMC). Accessed November 15, 2026.
  5. Efficacy and safety of varenicline for vaping cessation: a systematic review and meta-analysis of randomized controlled trials — PubMed (American Journal of Medicine). Accessed November 15, 2026.
  6. Efficacy and safety of varenicline for electronic cigarette cessation: a systematic review and meta-analysis — PubMed (Drug and Alcohol Dependence). Accessed November 15, 2026.
Disclaimer: the information on this site is for general reference only. It is not medical, legal or financial advice. Laws, rates and programs change, so check the official source before you rely on any detail.